Ryan Zimmerman

Does your prioritization of capital deployment change in the face of some of these inflationary pressures

I'm wondering how you think about the benefits of it? If there is increased business capture, does the growth profile of that business collectively change

The RPO and the, you know, specifically, service RPO was up really well

Just maybe you can kind of bridge us, I think, in terms of the twenty-sixth guide to those medium-term targets

are you suggesting or implied in that would be a decline in units just in terms of unit volume

The $25 million is that three quarters worth of sales or is there some disruption assumed there?

if you were to characterize the payer mix, particularly within the Medicaid population, what you could or could not be exposed to?

what did you see in terms of impact when you did that cutover that informs the U.S. plan? And how much of that 70 basis points was reflective of preparation

Your comments suggest you are still holding the line on tariff assumptions for the year. Where is your head at on tariff refunds

embedding for expectations on Acera, if you can provide any high-level commentary around it

how should we think about maybe what's contractually obligated over a certain time period or any other additional details

The program, the $500 million in cost weight, is that equal over the next 4 years? Is that upfront?

it does imply a little bit of a lower growth profile in the back -- in the fourth quarter, excuse me

what is holding you back or what isn't holding you back, I guess, to reaccelerate M&A as a contributor to Stryker's top line growth

I'm wondering if you kind of parse out between what is your ability to serve the market versus what may or may not be changes in demand

how would you characterize that trajectory would you characterize your confidence to achieve that

there's actually a local coverage determination this morning around total joint arthroplasty and robotics. I think specifically with CGS

how do you think about the health of the orthopedics market, how you're preparing to maybe capitalize on any disruption that may come of that and just kind of your outlook on orthopedic

when you think you can kind of really take Inari to a bigger international presence maybe than prior -- when it was a stand-alone company

I'd love your thoughts on kind of what you see as greenfield opportunity within Mako at this point? And obviously, an installed base number is always appreciated

the OUS hip number. It was pretty good, to say the least, and it stands out amongst the broader market

is there anything in there, particularly in the extremities line, that we should think about in terms of the momentum you're seeing

talk to us about what specifically changed there from those past 2 quarters where it was maybe trailing behind some of your other peers

Can you just talk about it, Ivan, in terms of what's driving that, how durable